(Q69074850)
Statements
Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens (English)
Weil-Hillman G
Fisch P
Prieve AF
Sosman JA
Hank JA